Literature DB >> 34470857

Liver-Dependent Lung Remodeling during Systemic Inflammation Shapes Responses to Secondary Infection.

Christine V Odom1,2, Yuri Kim1,3, Claire L Burgess1,4, Lillia A Baird1, Filiz T Korkmaz1, Elim Na1,4, Anukul T Shenoy1, Emad I Arafa1,4, TuKiet T Lam5,6, Matthew R Jones1,4, Joseph P Mizgerd1,2,4,7, Katrina E Traber1,4, Lee J Quinton8,2,3,4.   

Abstract

Systemic duress, such as that elicited by sepsis, burns, or trauma, predisposes patients to secondary pneumonia, demanding better understanding of host pathways influencing this deleterious connection. These pre-existing circumstances are capable of triggering the hepatic acute-phase response (APR), which we previously demonstrated is essential for limiting susceptibility to secondary lung infections. To identify potential mechanisms underlying protection afforded by the lung-liver axis, our studies aimed to evaluate liver-dependent lung reprogramming when a systemic inflammatory challenge precedes pneumonia. Wild-type mice and APR-deficient littermate mice with hepatocyte-specific deletion of STAT3 (hepSTAT3-/-), a transcription factor necessary for full APR initiation, were challenged i.p. with LPS to induce endotoxemia. After 18 h, pneumonia was induced by intratracheal Escherichia coli instillation. Endotoxemia elicited significant transcriptional alterations in the lungs of wild-type and hepSTAT3-/- mice, with nearly 2000 differentially expressed genes between genotypes. The gene signatures revealed exaggerated immune activity in the lungs of hepSTAT3-/- mice, which were compromised in their capacity to launch additional cytokine responses to secondary infection. Proteomics revealed substantial liver-dependent modifications in the airspaces of pneumonic mice, implicating a network of dispatched liver-derived mediators influencing lung homeostasis. These results indicate that after systemic inflammation, liver acute-phase changes dramatically remodel the lungs, resulting in a modified landscape for any stimuli encountered thereafter. Based on the established vulnerability of hepSTAT3-/- mice to secondary lung infections, we believe that intact liver function is critical for maintaining the immunological responsiveness of the lungs.
Copyright © 2021 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34470857      PMCID: PMC8631467          DOI: 10.4049/jimmunol.2100254

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  87 in total

Review 1.  Coagulation and innate immune responses: can we view them separately?

Authors:  Mieke Delvaeye; Edward M Conway
Journal:  Blood       Date:  2009-07-07       Impact factor: 22.113

2.  Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults.

Authors:  Seema Jain; Wesley H Self; Richard G Wunderink; Sherene Fakhran; Robert Balk; Anna M Bramley; Carrie Reed; Carlos G Grijalva; Evan J Anderson; D Mark Courtney; James D Chappell; Chao Qi; Eric M Hart; Frank Carroll; Christopher Trabue; Helen K Donnelly; Derek J Williams; Yuwei Zhu; Sandra R Arnold; Krow Ampofo; Grant W Waterer; Min Levine; Stephen Lindstrom; Jonas M Winchell; Jacqueline M Katz; Dean Erdman; Eileen Schneider; Lauri A Hicks; Jonathan A McCullers; Andrew T Pavia; Kathryn M Edwards; Lyn Finelli
Journal:  N Engl J Med       Date:  2015-07-14       Impact factor: 91.245

3.  Plasma carboxypeptidase U (CPU, CPB2, TAFIa) generation during in vitro clot lysis and its interplay between coagulation and fibrinolysis.

Authors:  Dorien Leenaerts; Jef Aernouts; Pieter Van Der Veken; Yani Sim; Anne-Marie Lambeir; Dirk Hendriks
Journal:  Thromb Haemost       Date:  2017-07-06       Impact factor: 5.249

Review 4.  Infection as a comorbidity of COPD.

Authors:  S Sethi
Journal:  Eur Respir J       Date:  2010-06       Impact factor: 16.671

5.  Alveolar macrophage deactivation in murine septic peritonitis: role of interleukin 10.

Authors:  R C Reddy; G H Chen; M W Newstead; T Moore; X Zeng; K Tateda; T J Standiford
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

6.  Endotoxin administration to humans primes alveolar macrophages for increased production of inflammatory mediators.

Authors:  P D Smith; A F Suffredini; J B Allen; L M Wahl; J E Parrillo; S M Wahl
Journal:  J Clin Immunol       Date:  1994-03       Impact factor: 8.317

7.  Critical role for granulocyte colony-stimulating factor in inflammatory arthritis.

Authors:  Kate E Lawlor; Ian K Campbell; Donald Metcalf; Kristy O'Donnell; Annemarie van Nieuwenhuijze; Andrew W Roberts; Ian P Wicks
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-22       Impact factor: 11.205

8.  IL-10 is a major mediator of sepsis-induced impairment in lung antibacterial host defense.

Authors:  M L Steinhauser; C M Hogaboam; S L Kunkel; N W Lukacs; R M Strieter; T J Standiford
Journal:  J Immunol       Date:  1999-01-01       Impact factor: 5.422

9.  Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway.

Authors:  S Akira; Y Nishio; M Inoue; X J Wang; S Wei; T Matsusaka; K Yoshida; T Sudo; M Naruto; T Kishimoto
Journal:  Cell       Date:  1994-04-08       Impact factor: 41.582

10.  Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study.

Authors:  Naohiko Nakamura; Etsuro Hatano; Kohta Iguchi; Motohiko Sato; Hiroaki Kawaguchi; Iwao Ohtsu; Takaki Sakurai; Nobuhiro Aizawa; Hiroko Iijima; Shuhei Nishiguchi; Takuya Tomono; Yukihiro Okuda; Seidai Wada; Satoru Seo; Kojiro Taura; Shinji Uemoto; Masaya Ikegawa
Journal:  BMC Cancer       Date:  2019-06-25       Impact factor: 4.430

View more
  1 in total

1.  Neutrophil-mediated delivery of the combination of colistin and azithromycin for the treatment of bacterial infection.

Authors:  Jiacong Gao; Xueyan Hu; Congjuan Xu; Mingming Guo; Shouyi Li; Fan Yang; Xiaolei Pan; Fangyu Zhou; Yongxin Jin; Fang Bai; Zhihui Cheng; Zhenzhou Wu; Shuiping Chen; Xinglu Huang; Weihui Wu
Journal:  iScience       Date:  2022-08-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.